Equities research analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) to report sales of $87.77 million for the current quarter, according to Zacks. Four analysts have issued estimates for Harmony Biosciences’ earnings, with estimates ranging from $86.88 million to $88.80 million. Harmony Biosciences reported sales of $59.67 million during the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Harmony Biosciences will report full-year sales of $429.99 million for the current year, with estimates ranging from $414.77 million to $443.20 million. For the next fiscal year, analysts expect that the firm will post sales of $604.57 million, with estimates ranging from $569.90 million to $665.40 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Harmony Biosciences.
Harmony Biosciences (NASDAQ:HRMY – Get Rating) last posted its earnings results on Monday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.02. Harmony Biosciences had a return on equity of 75.85% and a net margin of 11.33%. During the same period in the previous year, the firm earned $0.25 EPS.
In related news, Director Jack Nielsen sold 1,027 shares of Harmony Biosciences stock in a transaction on Monday, April 4th. The shares were sold at an average price of $50.00, for a total transaction of $51,350.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John C. Jacobs sold 15,000 shares of Harmony Biosciences stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $45.32, for a total transaction of $679,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 617,757 shares of company stock valued at $27,338,731. Insiders own 28.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. raised its position in shares of Harmony Biosciences by 352.2% during the 4th quarter. Advisor Group Holdings Inc. now owns 615 shares of the company’s stock valued at $28,000 after buying an additional 479 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Harmony Biosciences in the 4th quarter worth about $84,000. Royal Bank of Canada raised its position in Harmony Biosciences by 242.2% in the 2nd quarter. Royal Bank of Canada now owns 2,293 shares of the company’s stock worth $65,000 after purchasing an additional 1,623 shares during the period. Citigroup Inc. raised its position in Harmony Biosciences by 36.6% in the 3rd quarter. Citigroup Inc. now owns 2,931 shares of the company’s stock worth $112,000 after purchasing an additional 785 shares during the period. Finally, Mutual of America Capital Management LLC purchased a new stake in Harmony Biosciences in the 4th quarter worth about $133,000. Institutional investors and hedge funds own 53.82% of the company’s stock.
Shares of NASDAQ HRMY traded down $2.64 during trading hours on Monday, hitting $47.15. The company’s stock had a trading volume of 448,365 shares, compared to its average volume of 398,214. The company has a debt-to-equity ratio of 1.02, a quick ratio of 5.21 and a current ratio of 5.29. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 81.29 and a beta of 0.51. Harmony Biosciences has a 12 month low of $25.09 and a 12 month high of $52.75. The business has a 50-day simple moving average of $43.79 and a 200-day simple moving average of $40.72.
About Harmony Biosciences (Get Rating)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- Get a free copy of the StockNews.com research report on Harmony Biosciences (HRMY)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.